You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameCefazolin
Accession NumberDB01327
TypeSmall Molecule
GroupsApproved
Description

A semisynthetic cephalosporin analog with broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. [PubChem]

Structure
Thumb
Synonyms
SynonymLanguageCode
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acidNot AvailableNot Available
CefamezinNot AvailableNot Available
CefazolinaNot AvailableNot Available
CefazolineNot AvailableINN
CefazolinumNot AvailableNot Available
CephamezineNot AvailableNot Available
CephazolidinNot AvailableNot Available
CephazolinNot AvailableNot Available
CephazolineNot AvailableNot Available
CEZNot AvailableNot Available
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cefazolin Sodiumsolution1 g/50mLintravenousB. Braun Medical Inc.2000-07-27Not AvailableUs
Cefazolin Sodiumsolution2 g/50mLintravenousB. Braun Medical Inc.2012-01-13Not AvailableUs
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Cefazolininjection, powder, for solution20 gintravenousWest ward Pharmaceutical Corp2004-10-18Not AvailableUs
Cefazolininjection, powder, for solution225 mg/mLintramuscular; intravenousWest ward Pharmaceutical Corp2001-09-18Not AvailableUs
Cefazolininjection, powder, for solution330 mg/mLintramuscular; intravenousWest ward Pharmaceutical Corp2001-09-18Not AvailableUs
Cefazolininjection, powder, for solution10 gintravenousWest ward Pharmaceutical Corp2004-10-18Not AvailableUs
Cefazolininjection, solution1 g/50mLintravenousBaxter Healthcare Corporation1991-03-28Not AvailableUs
Cefazolininjection, powder, for solution1 g/3mLintramuscular; intravenousHospira, Inc.2009-03-24Not AvailableUs
Cefazolininjection, powder, for solution10 gintravenousHospira, Inc.2009-03-24Not AvailableUs
Cefazolininjection, powder, for solution1 gintravenousHospira, Inc2007-05-09Not AvailableUs
Cefazolininjection, powder, for solution500 mgintramuscular; intravenous; parenteralSandoz Inc1988-12-09Not AvailableUs
Cefazolininjection, powder, for solution1 gintramuscular; intravenous; parenteralSandoz Inc1988-12-09Not AvailableUs
Cefazolininjection, powder, for solution10 gintravenous; parenteralSandoz Inc1988-12-09Not AvailableUs
Cefazolininjection, powder, for solution500 mgintramuscular; intravenous; parenteralSandoz Inc1988-12-09Not AvailableUs
Cefazolininjection, powder, for solution500 mg/2.2mLintramuscular; intravenousSagent Pharmaceuticals2009-02-01Not AvailableUs
Cefazolininjection, powder, for solution1 g/3mLintramuscular; intravenousSagent Pharmaceuticals2009-02-01Not AvailableUs
Cefazolininjection, powder, for solution10 gintravenousSagent Pharmaceuticals2009-04-01Not AvailableUs
Cefazolininjection, powder, for solution500 mgintravenousWG Critical Care, LLC2013-12-20Not AvailableUs
Cefazolininjection, powder, for solution1 gintravenousWG Critical Care, LLC2013-12-20Not AvailableUs
Cefazolininjection, powder, for solution10 gintravenousWG Critical Care, LLC2014-03-03Not AvailableUs
Cefazolinpowder1 g/gintramuscular; intravenousGeneral Injectables & Vaccines, Inc2010-07-01Not AvailableUs
Cefazolininjection, powder, for solution1 g/3mLintramuscular; intravenousGeneral Injectables & Vaccines, Inc2011-09-07Not AvailableUs
Cefazolininjection, powder, for solution500 mg/500mgintramuscular; intravenousGeneral Injectables & Vaccines, Inc2012-04-12Not AvailableUs
Cefazolininjection, powder, for solution500 mg/500mgintramuscular; intravenousGeneral Injectables & Vaccines, Inc.2010-03-01Not AvailableUs
Cefazolininjection500 mg/10mLintramuscularPhysicians Total Care, Inc.2003-09-15Not AvailableUs
Cefazolininjection, powder, for solution1 gintravenousCardinal Health2007-05-09Not AvailableUs
Cefazolininjection, powder, for solution1 gintramuscular; intravenous; parenteralCardinal Health1988-12-09Not AvailableUs
Cefazolininjection, powder, for solution1 gintramuscular; intravenous; parenteralCardinal Health1988-12-09Not AvailableUs
Cefazolininjection, powder, for solution1 gintramuscular; intravenousCardinal Health2005-10-07Not AvailableUs
Cefazolininjection, powder, for solution1 gintramuscular; intravenousCardinal Health2012-04-20Not AvailableUs
Cefazolininjection1 gintramuscular; intravenousCardinal Health2001-09-18Not AvailableUs
Cefazolinpowder, for solution1 g/3mLintramuscular; intravenousCardinal Health2011-07-15Not AvailableUs
Cefazolininjection, powder, for solution500 mgintramuscular; intravenousApotex Corp2005-10-07Not AvailableUs
Cefazolininjection, powder, for solution1 gintramuscular; intravenousApotex Corp2005-10-07Not AvailableUs
Cefazolininjection, powder, for solution10 gintravenousApotex Corp2006-06-13Not AvailableUs
Cefazolininjection, powder, for solution1 gintramuscular; intravenousApotex Corp2012-04-20Not AvailableUs
Cefazolininjection, powder, for solution10 gintravenousApotex Corp2012-04-20Not AvailableUs
Cefazolinpowder, for solution500 mg/2.2mLintramuscular; intravenousAPP Pharmaceuticals, LLC2011-07-15Not AvailableUs
Cefazolinpowder, for solution1 g/3mLintramuscular; intravenousAPP Pharmaceuticals, LLC2011-07-15Not AvailableUs
Cefazolinpowder, for solution10 gintravenousAPP Pharmaceuticals, LLC2011-06-14Not AvailableUs
Cefazolininjection, powder, for solution20 g/100mLintravenousAPP Pharmaceuticals, LLC2012-07-13Not AvailableUs
Cefazolininjection, powder, lyophilized, for solution100 gintravenousSamson Medical Technologies, L.L.C.2007-01-01Not AvailableUs
Cefazolininjection, powder, lyophilized, for solution300 gintravenousSamson Medical Technologies, L.L.C.2007-01-01Not AvailableUs
Cefazolininjection, powder, for solution1 g/3mLintramuscular; intravenousDispensing Solutions, Inc.2009-02-01Not AvailableUs
Over the Counter ProductsNot Available
International Brands
NameCompany
AncefNot Available
ElzogramLilly
KefzolLilly
ZolicefBristol-Myers Squibb
Brand mixturesNot Available
Salts
Name/CASStructureProperties
Cefazolin sodium
27164-46-1
Thumb
  • InChI Key: FLKYBGKDCCEQQM-WYUVZMMLSA-M
  • Monoisotopic Mass: 476.011957689
  • Average Mass: 476.489
DBSALT000310
Categories
CAS number25953-19-9
WeightAverage: 454.507
Monoisotopic: 454.030013046
Chemical FormulaC14H14N8O4S3
InChI KeyMLYYVTUWGNIJIB-BXKDBHETSA-N
InChI
InChI=1S/C14H14N8O4S3/c1-6-17-18-14(29-6)28-4-7-3-27-12-9(11(24)22(12)10(7)13(25)26)16-8(23)2-21-5-15-19-20-21/h5,9,12H,2-4H2,1H3,(H,16,23)(H,25,26)/t9-,12-/m1/s1
IUPAC Name
(6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[2-(1H-1,2,3,4-tetrazol-1-yl)acetamido]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
SMILES
[H][C@]12SCC(CSC3=NN=C(C)S3)=C(N1C(=O)[C@H]2NC(=O)CN1C=NN=N1)C(O)=O
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as cephalosporins. These are compounds containing a 1,2-thiazine fused to a 2-azetidinone to for a oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid moiety or a derivative thereof.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassLactams
Sub ClassBeta lactams
Direct ParentCephalosporins
Alternative Parents
Substituents
  • Cephalosporin
  • N-acyl-alpha amino acid or derivatives
  • Alpha-amino acid or derivatives
  • Alkylarylthioether
  • Meta-thiazine
  • Heteroaromatic compound
  • Thiadiazole
  • Tetrazole
  • Tertiary carboxylic acid amide
  • Azole
  • Tertiary amine
  • Secondary carboxylic acid amide
  • Carboxamide group
  • Azetidine
  • Azacycle
  • Dialkylthioether
  • Sulfenyl compound
  • Hemithioaminal
  • Thioether
  • Monocarboxylic acid or derivatives
  • Enamine
  • Carboxylic acid
  • Carboxylic acid derivative
  • Carboxylic acid amide
  • Hydrocarbon derivative
  • Organosulfur compound
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External Descriptors
Pharmacology
IndicationMainly used to treat bacterial infections of the skin. It can also be used to treat moderately severe bacterial infections involving the lung, bone, joint, stomach, blood, heart valve, and urinary tract. It is clinically effective against infections caused by staphylococci and streptococci species of Gram positive bacteria. May be used for surgical prophylaxis; if required metronidazole may be added to cover B. fragilis.
PharmacodynamicsCefazolin (also known as cefazoline or cephazolin) is a semi-synthetic first generation cephalosporin for parenteral administration. Cefazolin has broad-spectrum antibiotic action due to inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine.
Mechanism of actionIn vitro tests demonstrate that the bactericidal action of cephalosporins results from inhibition of cell wall synthesis. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cell lysis is then mediated by bacterial cell wall autolytic enzymes such as autolysins.
AbsorptionNot absorbed from GI tract. Must be administered parenterally. Peak serum concentrations attained 1-2 hours post intramuscular injection.
Volume of distributionNot Available
Protein binding74-86%
Metabolism

Not metabolized.

Route of eliminationCefazolin is present in very low concentrations in the milk of nursing mothers. Cefazolin is excreted unchanged in the urine. In the first six hours approximately 60% of the drug is excreted in the urine and this increases to 70%-80% within 24 hours.
Half lifeThe serum half-life is approximately 1.8 hours following IV administration and approximately 2.0 hours following IM administration.
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Enteric bacteria and other eubacteria
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.5119
Blood Brain Barrier-0.987
Caco-2 permeable-0.7891
P-glycoprotein substrateSubstrate0.7863
P-glycoprotein inhibitor INon-inhibitor0.8663
P-glycoprotein inhibitor IINon-inhibitor0.9603
Renal organic cation transporterNon-inhibitor0.8574
CYP450 2C9 substrateNon-substrate0.7588
CYP450 2D6 substrateNon-substrate0.818
CYP450 3A4 substrateNon-substrate0.5161
CYP450 1A2 substrateNon-inhibitor0.8949
CYP450 2C9 substrateNon-inhibitor0.8746
CYP450 2D6 substrateNon-inhibitor0.9178
CYP450 2C19 substrateNon-inhibitor0.8363
CYP450 3A4 substrateNon-inhibitor0.9377
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.6362
Ames testNon AMES toxic0.6675
CarcinogenicityNon-carcinogens0.8876
BiodegradationNot ready biodegradable0.7464
Rat acute toxicity2.2215 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8898
hERG inhibition (predictor II)Non-inhibitor0.8711
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Injectionintramuscular500 mg/10mL
Injectionintramuscular; intravenous1 g
Injection, powder, for solutionintramuscular; intravenous1 g
Injection, powder, for solutionintramuscular; intravenous1 g/3mL
Injection, powder, for solutionintramuscular; intravenous225 mg/mL
Injection, powder, for solutionintramuscular; intravenous330 mg/mL
Injection, powder, for solutionintramuscular; intravenous500 mg
Injection, powder, for solutionintramuscular; intravenous500 mg/2.2mL
Injection, powder, for solutionintramuscular; intravenous500 mg/500mg
Injection, powder, for solutionintramuscular; intravenous; parenteral1 g
Injection, powder, for solutionintramuscular; intravenous; parenteral500 mg
Injection, powder, for solutionintravenous1 g
Injection, powder, for solutionintravenous10 g
Injection, powder, for solutionintravenous20 g
Injection, powder, for solutionintravenous20 g/100mL
Injection, powder, for solutionintravenous500 mg
Injection, powder, for solutionintravenous; parenteral10 g
Injection, powder, lyophilized, for solutionintravenous100 g
Injection, powder, lyophilized, for solutionintravenous300 g
Injection, solutionintravenous1 g/50mL
Powderintramuscular; intravenous1 g/g
Powder, for solutionintramuscular; intravenous1 g/3mL
Powder, for solutionintramuscular; intravenous500 mg/2.2mL
Powder, for solutionintravenous10 g
Solutionintravenous1 g/50mL
Solutionintravenous2 g/50mL
Prices
Unit descriptionCostUnit
Cefazolin 10 g/vial58.66USD vial
Sterile Cefazolin Sodium 10 g/vial58.66USD vial
Cefazolin 20 gm bulk vial29.69USD vial
Cefazolin 10 gm vial24.0USD vial
Cefazolin 1 g/vial6.29USD vial
Sterile Cefazolin Sodium 1 g/vial6.29USD vial
Cefazolin 1 gm-d5w bag5.04USD each
Cefazolin 500 mg/vial4.19USD vial
Sterile Cefazolin Sodium 500 mg/vial4.19USD vial
Cefazolin 1 gm vial3.12USD vial
Cefazolin sod 100 gm bulk bag1.26USD g
Cefazolin sod-water 1 g/10 ml0.93USD ml
Cefazolin-d5w 2 g/100 ml0.17USD ml
Cefazolin-ns 2 g/100 ml0.08USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
logP-0.58HANSCH,C ET AL. (1995)
Predicted Properties
PropertyValueSource
Water Solubility0.487 mg/mLALOGPS
logP-0.4ALOGPS
logP-1.5ChemAxon
logS-3ALOGPS
pKa (Strongest Acidic)3.03ChemAxon
pKa (Strongest Basic)0.26ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area156.09 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity119.86 m3·mol-1ChemAxon
Polarizability41.44 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
SpectraNot Available
References
Synthesis Reference

Michael Bornstein, Sandra M. Carone, “Method of preparing sterile essentially amorphous cefazolin for reconstitution for parenteral administration.” U.S. Patent US4002748, issued August, 1967.

US4002748
General ReferenceNot Available
External Links
ATC CodesJ01DB04
AHFS Codes
  • 08:12.06.04
PDB EntriesNot Available
FDA labelDownload (54.2 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
AmikacinIncreased risk of nephrotoxicity
GentamicinIncreased risk of nephrotoxicity
NetilmicinIncreased risk of nephrotoxicity
ProbenecidProbenecid may increase the serum level of cefazolin.
TobramycinIncreased risk of nephrotoxicity
Food InteractionsNot Available

Targets

1. Penicillin-binding protein 1A

Kind: protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Penicillin-binding protein 1A P02918 Details

References:

  1. Yotsuji A, Mitsuyama J, Hori R, Yasuda T, Saikawa I, Inoue M, Mitsuhashi S: Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis. Antimicrob Agents Chemother. 1988 Dec;32(12):1848-53. Pubmed
  2. Truesdell SE, Zurenko GE, Laborde AL: Interaction of cephalosporins with penicillin-binding proteins of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1989 Apr;23 Suppl D:13-9. Pubmed

2. Penicillin-binding protein 1B

Kind: protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Penicillin-binding protein 1B P02919 Details

References:

  1. Truesdell SE, Zurenko GE, Laborde AL: Interaction of cephalosporins with penicillin-binding proteins of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1989 Apr;23 Suppl D:13-9. Pubmed
  2. Yotsuji A, Mitsuyama J, Hori R, Yasuda T, Saikawa I, Inoue M, Mitsuhashi S: Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis. Antimicrob Agents Chemother. 1988 Dec;32(12):1848-53. Pubmed

3. Penicillin-binding protein 1C

Kind: protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Penicillin-binding protein 1C P76577 Details

References:

  1. Truesdell SE, Zurenko GE, Laborde AL: Interaction of cephalosporins with penicillin-binding proteins of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1989 Apr;23 Suppl D:13-9. Pubmed
  2. Yotsuji A, Mitsuyama J, Hori R, Yasuda T, Saikawa I, Inoue M, Mitsuhashi S: Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis. Antimicrob Agents Chemother. 1988 Dec;32(12):1848-53. Pubmed

4. Penicillin-binding protein 2

Kind: protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Penicillin-binding protein 2 P0AD65 Details

References:

  1. Truesdell SE, Zurenko GE, Laborde AL: Interaction of cephalosporins with penicillin-binding proteins of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1989 Apr;23 Suppl D:13-9. Pubmed
  2. Yotsuji A, Mitsuyama J, Hori R, Yasuda T, Saikawa I, Inoue M, Mitsuhashi S: Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis. Antimicrob Agents Chemother. 1988 Dec;32(12):1848-53. Pubmed

5. Peptidoglycan synthase FtsI

Kind: protein

Organism: Escherichia coli (strain K12)

Pharmacological action: yes

Actions: inhibitor

Components

Name UniProt ID Details
Peptidoglycan synthase FtsI P0AD68 Details

References:

  1. Truesdell SE, Zurenko GE, Laborde AL: Interaction of cephalosporins with penicillin-binding proteins of methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother. 1989 Apr;23 Suppl D:13-9. Pubmed
  2. Yotsuji A, Mitsuyama J, Hori R, Yasuda T, Saikawa I, Inoue M, Mitsuhashi S: Mechanism of action of cephalosporins and resistance caused by decreased affinity for penicillin-binding proteins in Bacteroides fragilis. Antimicrob Agents Chemother. 1988 Dec;32(12):1848-53. Pubmed

6. Serum paraoxonase/arylesterase 1

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Serum paraoxonase/arylesterase 1 P27169 Details

References:

  1. Sinan S, Kockar F, Arslan O: Novel purification strategy for human PON1 and inhibition of the activity by cephalosporin and aminoglikozide derived antibiotics. Biochimie. 2006 May;88(5):565-74. Epub 2006 Jan 19. Pubmed

Enzymes

1. Thiopurine S-methyltransferase

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Thiopurine S-methyltransferase P51580 Details

References:

  1. Kerremans AL, Lipsky JJ, Van Loon J, Gallego MO, Weinshilboum RM: Cephalosporin-induced hypoprothrombinemia: possible role for thiol methylation of 1-methyltetrazole-5-thiol and 2-methyl-1,3,4-thiadiazole-5-thiol. J Pharmacol Exp Ther. 1985 Nov;235(2):382-8. Pubmed
  2. Wood TC, Johnson KL, Naylor S, Weinshilboum RM: Cefazolin administration and 2-methyl-1,3,4-thiadiazole-5-thiol in human tissue: possible relationship to hypoprothrombinemia. Drug Metab Dispos. 2002 Oct;30(10):1123-8. Pubmed

Carriers

1. Serum albumin

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: other/unknown

Components

Name UniProt ID Details
Serum albumin P02768 Details

References:

  1. Bratlid D, Bergan T: Displacement of albumin-bound antimicrobial agents by bilirubin. Pharmacology. 1976;14(5):464-72. Pubmed
  2. Decroix MO, Zini R, Chaumeil JC, Tillement JP: Cefazolin serum protein binding and its inhibition by bilirubin, fatty acids and other drugs. Biochem Pharmacol. 1988 Jul 15;37(14):2807-14. Pubmed
  3. Ichimura F, Matsushita R, Tsuji A, Deguchi Y: Mutual interaction between bilirubin and cefazolin in binding to human serum albumin. J Pharm Sci. 1990 Nov;79(11):1041-2. Pubmed

Transporters

1. Multidrug resistance-associated protein 4

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate

Components

Name UniProt ID Details
Multidrug resistance-associated protein 4 O15439 Details

References:

  1. Ci L, Kusuhara H, Adachi M, Schuetz JD, Takeuchi K, Sugiyama Y: Involvement of MRP4 (ABCC4) in the luminal efflux of ceftizoxime and cefazolin in the kidney. Mol Pharmacol. 2007 Jun;71(6):1591-7. Epub 2007 Mar 7. Pubmed

2. Solute carrier family 22 member 6

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: substrate inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 6 Q4U2R8 Details

References:

  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. Pubmed
  2. Jariyawat S, Sekine T, Takeda M, Apiwattanakul N, Kanai Y, Sophasan S, Endou H: The interaction and transport of beta-lactam antibiotics with the cloned rat renal organic anion transporter 1. J Pharmacol Exp Ther. 1999 Aug;290(2):672-7. Pubmed
  3. Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8;70(16):1861-74. Pubmed
  4. Uwai Y, Saito H, Inui K: Rat renal organic anion transporter rOAT1 mediates transport of urinary-excreted cephalosporins, but not of biliary-excreted cefoperazone. Drug Metab Pharmacokinet. 2002;17(2):125-9. Pubmed

3. Solute carrier family 22 member 8

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 8 Q8TCC7 Details

References:

  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. Pubmed
  2. Jung KY, Takeda M, Shimoda M, Narikawa S, Tojo A, Kim DK, Chairoungdua A, Choi BK, Kusuhara H, Sugiyama Y, Sekine T, Endou H: Involvement of rat organic anion transporter 3 (rOAT3) in cephaloridine-induced nephrotoxicity: in comparison with rOAT1. Life Sci. 2002 Mar 8;70(16):1861-74. Pubmed
  3. Ohtsuki S, Asaba H, Takanaga H, Deguchi T, Hosoya K, Otagiri M, Terasaki T: Role of blood-brain barrier organic anion transporter 3 (OAT3) in the efflux of indoxyl sulfate, a uremic toxin: its involvement in neurotransmitter metabolite clearance from the brain. J Neurochem. 2002 Oct;83(1):57-66. Pubmed

4. Solute carrier family 22 member 11

Kind: protein

Organism: Human

Pharmacological action: unknown

Actions: inhibitor

Components

Name UniProt ID Details
Solute carrier family 22 member 11 Q9NSA0 Details

References:

  1. Takeda M, Babu E, Narikawa S, Endou H: Interaction of human organic anion transporters with various cephalosporin antibiotics. Eur J Pharmacol. 2002 Mar 8;438(3):137-42. Pubmed

Comments
comments powered by Disqus
Drug created on June 30, 2007 11:22 / Updated on September 16, 2013 17:14